Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2020 May 19;19(7):1562–1571. doi: 10.1158/1535-7163.MCT-19-1036

Figure 1. Genomic alterations in genes involved in PI3K/Akt/mTOR signaling in HNSCC.

Figure 1.

(A) Frequency of genomic alterations in genes involved in PI3K/Akt/mTOR signaling in the HNSCC TCGA dataset (n = 504), including HPV-positive (n = 95) and negative (n = 409) lesions. (B) Comparison of overall survival between patients with and without copy number loss of tumor suppressor genes (TSGs) in either PTEN, TSC1, TSC2, STK11, or EIF4E-BP1. (C) Isogenic cell panels of HNSCC cell lines, CAL27 and HN12, parental controls and with gene knockout in PTEN, TSC2, STK11, or EIF4E-BP1, as indicated.